妊娠早期钆基对比剂暴露:美国460万妊娠的使用研究
该回顾性研究利用Sentinel分布式数据库,识别2006至2017年间美国16个数据合作方中活产妊娠,评估妊娠期钆基对比剂(GBCA)暴露的患病率。在4 692 744例活产妊娠中,共5457例妊娠发生6879次GBCA暴露,相当于每860例妊娠中有1次增强MRI(占所有妊娠的0.12%)。大多数增强MRI检查位于头部(n=3499),盆腔和腹部MRI占孕期所有增强MRI的22.3%(n=1536)。70.2%的GBCA暴露发生在妊娠早期,其患病率分别为妊娠中期的4.3倍和妊娠晚期的5.1倍。
要点
- 孕期GBCA暴露总患病率为每860例妊娠1次(0.12%)。
- 70.2%的GBCA暴露发生在妊娠早期,妊娠早期暴露患病率为妊娠中期的4.3倍、妊娠晚期的5.1倍。
- 孕期增强MRI最常见部位为头部(n=3499),盆腔和腹部MRI占22.3%(n=1536)。
核心结论
- 研究识别出妊娠最初几周的GBCA暴露率高于妊娠后期,提示可能在确认妊娠之前发生非故意暴露。
研究设计与样本
- 回顾性利用Sentinel分布式数据库,从16个数据合作方识别2006至2017年间美国活产妊娠,比较妊娠妇女与匹配对照妇女中伴或不伴GBCA的MRI检查患病率。
诊断标准与关键数值
- 主要结局为妊娠妇女及匹配对照妇女中伴或不伴GBCA的MRI检查患病率,按解剖部位和孕期排序。
- 在4 692 744例活产妊娠中,5457例妊娠发生6879次GBCA暴露,相当于每860例妊娠1次增强MRI(占所有妊娠的0.12%)。
- 孕期增强MRI中头部检查n=3499,盆腔和腹部MRI占22.3%(n=1536)。
- 70.2%的GBCA暴露发生在妊娠早期,其患病率为妊娠中期的4.3倍、妊娠晚期的5.1倍。
临床应用与阅片要点
- 原文指出,除非对妇女或胎儿健康至关重要,否则不推荐妊娠期使用GBCA。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BackgroundThe safety of gadolinium-based contrast agent (GBCA) exposure during pregnancy has not been established, and the use of GBCAs during pregnancy is not recommended unless it is essential to the health of the woman or fetus.PurposeTo examine the prevalence of GBCA exposure in a large sample of pregnancies resulting in a live birth.Materials and MethodsThe Sentinel Distributed Database was used to retrospectively identify U.S. pregnancies that resulted in live births between 2006 and 2017 from 16 data partners. The main outcome was the prevalence of MRI procedures with and without GBCAs, sorted by anatomic location and trimester, among pregnant and matched comparator women.ResultsAmong 4 692 744 pregnancies resulting in a live birth, we identified 6879 exposures to GBCAs in 5457 pregnancies, representing one contrast-enhanced MRI examination per 860 pregnancies (0.12% of all pregnancies). Most contrast-enhanced MRI examinations were performed in the head (n = 3499), although pelvic and abdominal MRI constituted 22.3% (n = 1536) of all contrast-enhanced MRI examinations during pregnancy. The majority (70.2%) of GBCA exposures occurred during the first trimester, with a 4.3-fold greater prevalence compared with that in the second trimester and a 5.1-fold greater prevalence compared with that in the third trimester.ConclusionThis study identified higher rates of gadolinium-based contrast agent (GBCA) exposure during the first few weeks of pregnancy compared with the later weeks of pregnancy, suggesting inadvertent exposure to GBCAs might occur before pregnancy is recognized.© RSNA, 2019Online supplemental material is available for this article.See also the editorial by Kallmes and Watson in this issue.
引用
- Bird ST, Gelperin K, Sahin L, et al. First-Trimester Exposure to Gadolinium-based Contrast Agents: A Utilization Study of 4.6 Million U.S. Pregnancies. Radiology. 2019. PMID: 31429682. doi:10.1148/radiol.2019190563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。